Sequella Home Page

Latest News

Infectex Announces Positive Phase 2b-3 Clinical Trial Results of SQ109 for the
Treatment of Multidrug-Resistant Pulmonary Tuberculosis

Sequella Acquires Exclusive Worldwide Rights to Pfizer's Sutezolid, Currently in Clinical Development for Tuberculosis

Sequella's Lead Antitubercular Drug Candidate SQ109 Begins Phase 2b Clinical Trial in Africa

Maxwell Biotech Venture Fund’s Portfolio Company, Infectex, Enrolls First Multi-Drug Resistant Tuberculosis (MDR-TB) Patients in Pivotal Clinical Trial of SQ109, Licensed from Sequella

LabCorp Enters Into License Agreement with Sequella for use of B-SMART™ Technology to develop Rapid Tuberculosis Antimicrobial Susceptibility Test

Welcome to Sequella

Sequella is a clinical stage antiinfectives company focused on discovering, developing, and commercializing improved treatments for serious infectious diseases. The company leverages its global influence, R&D platforms and infectious disease expertise to proactively address emerging health threats. Through focused execution, clear commercialization pathways, and strategic partnerships with local and global pharmaceutical companies, Sequella is working to commercialize a broad product portfolio designed to treat infectious disease threats with significant market opportunity.


Sequella's growth strategy leverages a strong management team and core competencies in chemistry, microbiology, molecular biology, infectious diseases, and product development. The company's product portfolio addresses disease areas of known or suspected infectious etiology:


Mycobacterium tuberculosis infections including drug-suceptible TB, multidrug-resistant TB (MDR-TB), and extremely drug-resistant TB (XDR-TB) indications. Products in our pipeline include two drug candidates that have each completed a phase 2 clinical trial (SQ109, Sutezolid), one preclinical drug candidate (SQ609), and a novel rapid antibiotic susceptibility test (B-SMART™).


Helicobacter pylori infections, which can cause gastric and duodenal ulcers and gastric cancer. SQ109 is in Phase 2 clinical trials for this indication.


Clostridium difficile infections,which can cause life-threatening diarrhea. SQ641 is a preclinical stage drug candidate for this indication.


M. avium paratuberculosis and other nontuberculous mycobacterial infections, which are responsible for Buruli ulcer and have also been implicated in Crohn's disease. SQ641 is a preclinical stage drug candidate for this indication.


Please see our Executive Summary for more information on the company and our products.